Abstract: The present invention relates to a pharmaceutical composition for the treatment of colon and lung cancer comprising a MKK4 inhibitor and a MEK, ERK, KRAS or SHP2 inhibitor. The composition provides a strong synergistic effect in the treatment of colon and lung cancer and in particular in the treatment of KRAS mutant colon and lung cancer.

Abstract: The invention relates to an inducer of senescence, in combination with a short-lived, selective Death Receptor 5 (DR5) agonist, for use in a method of treating a patient suffering from a tumor. The invention further relates to a pharmaceutical composition, comprising a short-lived, selective Death Receptor 5 (DR5) agonist and, optionally, an inducer of senescence. The invention further relates to methods of treating a patient having a tumor, and to a selective, short-lived DR5 agonist, for use in a method of selectively killing senescent cells, including senescent cancer cells.

Abstract: This invention provides compositions of (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, checkpoint kinase 1 (“CHK1”) inhibitor, B-cell lymphoma-extra large (“BCL-xL”) inhibitor, BCL-xL proteolysis-targeting chimera (“BCL-xL PROTAC”), pan-BCL inhibitor or ataxia telangiectasia and Rad3-related (“ATR”) inhibitor. This invention further provides methods for treating cancer or for preventing, inhibiting, or reducing risk of metastasis of a cancer, such as colorectal cancer, cholangiocarcinoma, pancreatic cancer or ovarian cancer, using (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, CHK1 inhibitor, BCL-xL inhibitor, BCL-xL PROTAC, pan-BCL inhibitor or ATR inhibitor.

Abstract: The invention relates to a method of treating a patient suffering from a carcinoma, especially a hepatocellular carcinoma. The methods of the invention employ a specific combination of two protein kinase inhibitors, comprising lenvatinib and an Epidermal Growth Factor Receptor (EGFR) inhibitor. The invention further relates to a pharmaceutical preparation comprising lenvatinib and an EGFR inhibitor, a kit of parts, comprising lenvatinib and an EGFR inhibitor, and to the use of the pharmaceutical preparation or the kit of parts in a method of treating a patient suffering from a hepatocellular carcinoma.

Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.

Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The invention relates to methods and means of typing a sample from a breast cancer patient, preferably an invasive lobular breast cancer patient. The invention further relates to methods of assigning treatment to a patient suffering from invasive lobular breast cancer, and to methods of treating a patient suffering from invasive lobular breast cancer.

Abstract: The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer.

Abstract: The invention relates to a method of predicting whether a breast cancer patient is or becomes resistant to anti-estrogen directed therapy. More specifically, the invention relates to methods and means for typing of breast cancer cells as having a good or a poor outcome to anti-estrogen directed therapy. The invention further relates to methods of assigning therapy to a breast cancer patient.

Abstract: The invention relates to methods for determining the presence or absence of striatin-anaplastic lymphoma kinase (STRN-ALK) gene fusion and/or a Fibroblast Growth Factor Receptor 3—transforming acidic coiled-coil containing protein 3 (FGFR3-TACC3) gene fusion in an individual, especially an individual suffering from lung cancer. The invention further relates to a method for diagnosing an individual as having adenocarcinoma, and to a method for treating said individual. The invention additionally relates to a method for diagnosing an individual as having squamous cell carcinoma, and to a method for treating said individual.

Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.

Abstract: The present invention relates to methods of typing a sample from an individual suffering from cancer. The invention further relates to methods for assigning treatment to an individual suffering from cancer, comprising typing a sample from an individual suffering from cancer according to the methods of the invention.

Abstract: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a lung cancer patient, wherein a reduced expression of a MEDIATOR and/or SW1/SNF complex gene in the lung cancer cells of the patient indicates that the lung cancer cells in the patient may be resistant to treatment with a receptor tyrosine kinase inhibitor, such as gefitinib and/or erlotinib. In some embodiments, the invention relates to methods and related compositions for predicting resistance to anticancer treatment by detecting the expression levels of one or more TGF-beta pathway nucleic acids and/or proteins.

Abstract: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in. a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a breast cancer patient, wherein a reduced expression of a MEDIATOR and/or SWI/SNF complex gene in the breast cancer cells of the patient indicates that the breast cancer cells in the patient may be successfully treated with a PI3K and/or mTOR inhibitor.

Abstract: The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.